Blood pressure is critically controlled by angiotensins 1 , which are vasopressor peptides specifically released by the enzyme renin from the tail of angiotensinogen-a non-inhibitory member of the serpin family of protease inhibitors 2,3 . Although angiotensinogen has long been regarded as a passive substrate, the crystal structures solved here to 2.1 Å resolution show that the angiotensin cleavage site is inaccessibly buried in its amino-terminal tail. The conformational rearrangement that makes this site accessible for proteolysis is revealed in our 4.4 Å structure of the complex of human angiotensinogen with renin. The co-ordinated changes involved are seen to be critically linked by a conserved but labile disulphide bridge. Here we show that the reduced unbridged form of angiotensinogen is present in the circulation in a near 40:60 ratio with the oxidized sulphydryl-bridged form, which preferentially interacts with receptorbound renin. We propose that this redox-responsive transition of angiotensinogen to a form that will more effectively release angiotensin at a cellular level contributes to the modulation of blood pressure. Specifically, we demonstrate the oxidative switch of angiotensinogen to its more active sulphydryl-bridged form in the maternal circulation in pre-eclampsia-the hypertensive crisis of pregnancy that threatens the health and survival of both mother and child.
Blood pressure is critically controlled by angiotensins 1 , which are vasopressor peptides specifically released by the enzyme renin from the tail of angiotensinogen-a non-inhibitory member of the serpin family of protease inhibitors 2, 3 . Although angiotensinogen has long been regarded as a passive substrate, the crystal structures solved here to 2.1 Å resolution show that the angiotensin cleavage site is inaccessibly buried in its amino-terminal tail. The conformational rearrangement that makes this site accessible for proteolysis is revealed in our 4.4 Å structure of the complex of human angiotensinogen with renin. The co-ordinated changes involved are seen to be critically linked by a conserved but labile disulphide bridge. Here we show that the reduced unbridged form of angiotensinogen is present in the circulation in a near 40:60 ratio with the oxidized sulphydryl-bridged form, which preferentially interacts with receptorbound renin. We propose that this redox-responsive transition of angiotensinogen to a form that will more effectively release angiotensin at a cellular level contributes to the modulation of blood pressure. Specifically, we demonstrate the oxidative switch of angiotensinogen to its more active sulphydryl-bridged form in the maternal circulation in pre-eclampsia-the hypertensive crisis of pregnancy that threatens the health and survival of both mother and child.
The octapeptide angiotensin II that constricts arterial blood vessels is released from a precursor decapeptide, angiotensin I, by the angiotensin converting enzyme, ACE. Although studies of hypertension and its therapy have focused on ACE and its inhibitors, the initiating and rate-limiting step in the angiotensin pathway is the preceding release of angiotensin I, by the enzyme renin, from the N terminus of the much larger protein, angiotensinogen 1, 4 (Fig. 1a ). Previous attempts to determine the structure of plasma angiotensinogen were frustrated by its heterogeneity, and in order to obtain diffraction-quality crystals, we produced recombinant non-glycosylated angiotensinogens from mouse, rat and human by expression in Escherichia coli. Subsequent crystallization and X-ray diffraction yielded data sets that were solved as detailed in Methods. We determined the mouse structures at higher resolution (2.3, 2.1, 2.95 Å ), but the general features are preserved in the 3.15 Å rat and 3.3 Å human structures (as shown separately and with statistics in Supplementary Fig. 2 and Supplementary Table 1 ).
With the exception of the exposed and hence mobile reactive centre loop (residues 408-425), the overall results show the complete fold of the human molecule, including the full N-terminal extension with the renin cleavage site ( Fig. 1a ). Although angiotensinogen has only 22% sequence identity to its closest relatives amongst other serpins 3 , it substantially retains the typical serpin fold ( Supplementary Fig. 2 ). Of special interest, the structure shows that Met 235, the common polymorphism of which has been linked to hypertension, has a freely extended side-chain and is situated on an external peptide loop (hF-s3A) distant from the main functional sites on the molecule. This strengthens previous deductions 5, 6 that the predisposition to hypertension results from the small increase in concentration of the polymorphic angiotensinogen rather than a change in its function. The 63-residue N-terminal tail of angiotensinogen is seen as an ordered superstructure, anchored by two new helices, and with the renin-cleavage site, Leu 10-Val 11 in humans, held in an inaccessibly buried position. The change in fold allowing access to the buried cleavage site became apparent when we solved the structure of the complex of angiotensinogen and renin. Crystals of the initiating complex formed by human angiotensinogen with recombinantly inactivated human renin (Asp292Ala) gave X-ray diffraction to 4.4 Å resolution. The structure was solved by molecular replacement, as detailed in Methods. Although at low resolution, the structure of the complex clearly shows the mode of binding of renin and the associated localized changes in fold ( Fig. 1b, Supplementary Fig. 3 ).
In addition to the predicted 7,8 intimate interaction between the N-terminal substrate (angiotensin I) region of angiotensinogen and the active site cleft of renin, there is a substantial contact surface of 670 Å 2 between the bodies of the two proteins, primarily hydrophobic in nature. Helix A of angiotensinogen lies across the active site cleft of renin, and helix C and the CD-loop contact the N-terminal lobe of renin. The body of angiotensinogen substantially retains its fold except for a displacement of the CD-loop, which is enlarged and conserved in the angiotensinogens and would otherwise sterically block the binding of renin. The 10 Å shift of this CD loop is accompanied by a 10-20 Å extension and movement of the N-terminal substrate peptide of angiotensinogen into the active site cleft of renin with, as clearly seen in the Supplementary Video, the two concerted movements being linked by a disulphide bridge.
The functional significance of this Cys 18-Cys 138 bridge linking the angiotensin-containing tail of angiotensinogen to the body of the molecule had been indicated in earlier biochemical studies 9 . Human angiotensinogen contains four cysteines but those forming the Cys18-Cys 138 linkage are the only two conserved in all species 9, 10 . We now show ( Fig. 2a ) that this disulphide linkage is labile, with a redox titration of isolated angiotensinogen indicating a reduction potential for this dithiol/disulphide equilibrium of 2230 mV at 25 uC, pH 7 (Supplementary Fig. 4 ). That reduction does result in the breaking of the 18-138 bridge was confirmed in the crystal structure of reduced mouse angiotensinogen, with the likely structural and hence functional consequences being indicated by a change of thermal stability, from 62.6 uC for the constrained oxidized form to 57 uC for the relaxed reduced form ( Supplementary Fig. 5 ). Angiotensinogen is predictably secreted in the oxidized bridged form after passing through the endoplasmic reticulum, but will then be reduced by interaction with selective thiol-reductant systems in the plasma. The presence of the reduced as well as oxidized forms of angiotensinogen in the plasma is shown in Fig. 2b , with a remarkably consistent reduced-to-oxidized proportion, near 40:60 independent of gender or age, as shown below. Although this is a stable ratio in the plasma pool, the redox poise of the transition will predictably allow the reversible switch from the oxidized to reduced form in focal tissues or vascular beds. 
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The critical interactions of renin and angiotensinogen, with respect to the control of blood pressure, are now believed to occur in the renal tubules and tissue 11 . At these sites a third component, the cell-surface prorenin receptor, binds renin to give a considerable enhancement of its catalytic cleavage of angiotensinogen 12 . To assess the functional consequences of the oxidative transition, we recombinantly expressed and isolated fully glycosylated human angiotensinogen, human renin and human prorenin receptor. Incubation of the reduced and oxidized forms of angiotensinogen with renin ( Fig. 3a, Table 1 ) shows that the prorenin receptor although having little effect on the reduced form gives a fourfold increase in the renin-binding affinity (K m ) of the oxidized form, with a consequent fourfold increase in the catalytic release of angiotensin. This preferential binding and activation of the oxidized form of angiotensinogen by the prorenin receptor will particularly occur on cell surfaces, thus allowing a redox-sensitive and focal modulation of angiotensin release in specific tissues.
Although we demonstrate here the direct effects of the Cys 18-Cys 138 reduction on the substrate activity of angiotensinogen, the subsequent ligand modification of reduced disulphides is now also known to be widely involved in the modulation of activity in other proteins 13 . The potential for such modifications is pertinently 14 illustrated with a known hypotensive agent, nitric oxide. As shown in Fig. 3b , incubation of reduced angiotensinogen with the S-nitrosothiol donor SNAP 15, 16 leads to the stoichiometric loss of the 18 and 138 thiols, confirming the potential nitrosylation and hence blockage of both cysteines. Taken together with the structural evidence, these findings of the consequences of the redox transition of angiotensinogen strongly indicate an as yet unrecognized modulatory mechanism at the commencement of the principal pathway controlling vasoconstriction.
Previous indications of a redox-sensitive contribution to the control of blood pressure came from observations of the association of oxidative stress with the onset of episodic hypertension 17, 18 . Our suspicion that this could result from the oxidative conversion of angiotensinogen to its more active bridged form was difficult to confirm, as the critical release of angiotensins is likely to occur focally in renal tissue rather than in the plasma pool. A more overt occurrence however is the oxidative stress arising from placental dysfunction 14, 19 . This underlies 20,21 the hypertension that commonly complicates pregnancy and progresses in a quoted 2-7% of all pregnancies to the development of pre-eclampsia, a leading cause of perinatal and maternal mortality and morbidity in the developed world 22 . To determine, as proof of principle, if oxidative changes occurred in angiotensinogen in pre-eclampsia, we examined samples from a previous study of pre-eclamptic women 23 .
Twenty-four EDTA plasma samples, stored at -80 uC, 12 from women with strictly defined pre-eclampsia and 12 from gestation matched normotensive controls, were referred for analysis with a blinded coding. The proportion of reduced to oxidized angiotensinogen in each sample was then assessed by electrophoresis with western blotting and the gels compared with the control series in Fig. 4a . Visual examination of the 24 maternal samples (Fig. 4b) clearly indicated the presence of samples with a decreased proportion of reduced to oxidized angiotensinogen, allowing the ready recognition of 8 of the 12 preeclamptic plasmas before the breaking of the code. Unequivocal evidence of the occurrence of the oxidative transition in pre-eclampsia came from the samples with strikingly obvious decreases in reduced angiotensinogen, as asterisked in Fig. 4b , all of which were revealed to be from pre-eclamptics (see also Supplementary Fig. 6 ). Subsequent quantitative measurements (Fig. 4c ) confirm the visual observations from the gel and also the findings in studies of other plasma markers 23, 24 of an overlapping range of oxidative changes in pregnancy plasmafrom mild in normotensives to severe in pre-eclampsia. These changes in the plasma pool will be much more marked in the tissues. The more effective cleavage of the oxidized form of angiotensinogen by cellbound renin in these tissues thus provides a contributory causative link between the oxidative changes in pregnancy and the onset of the hypertension that is a defining feature of pre-eclampsia.
In conclusion, a central message from our findings is that the release of angiotensin requires a change in conformation in angiotensinogen to allow the access, as well as complementary binding, of renin. At the focus of this change is a labile disulphide bridge that readily undergoes a transition to a more active oxidized form and demonstrably does so in pre-eclampsia. Evidence that the fourfold change in activity that occurs on oxidation is a sufficient cause of pre-eclamptic hypertension comes from a fortuitous experiment of nature. A mutation at the renin cleavage site in angiotensinogen, Leu10Phe, has been previously detected in five heterozygotes, each identified because of an association with hypertension and specifically with hypertension in pregnancy. Investigation of the index case of a 17-year-old woman with pre-eclampsia 25 showed that the mutation resulted in an increased catalytic efficiency of cleavage of the angiotensinogen by renin, comparable to the change observed here with the transition of angiotensinogen from the reduced to oxidized form. Thus there is now a clear chain of evidence linking the oxidative changes in the placenta with the hypertension in pregnancy that leads on to the development of pre-eclampsia. The findings here will reinforce efforts to develop anti-oxidant therapies for pre-eclampsia 26 and will also open a means of monitoring the progress and management of the disorder. In a broader context, we draw attention to the hitherto 
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neglected contribution of angiotensinogen to the multifactorial processes that modulate blood pressure in humans.
METHODS SUMMARY
Crystals of angiotensinogen and the complex of human angiotensinogen with deglycosylated renin-Asp292Ala were grown at room temperature under conditions listed in Supplementary Table 1 . Data sets were collected at 100 K at the Daresbury and Diamond synchrotron light sources and processed with the CCP4 program suite. The structures of human, rat and mouse angiotensinogen were solved by molecular replacement in Phaser 27 , using an ensemble of distantly related serpins as the search model with additional phase information obtained from a GdCl 3 derivative of human angiotensinogen. The structure of the complex with renin was solved by molecular replacement using renin from PDB entry 2BKS 28 and its peptide complex from PDB entry 1SMR 7 . The structures were completed by refinement in Refmac5 29 and rebuilding in Coot 30 . Further details related to crystal structures and refinement, recombinant expression, thiol titration and nitrosylation and the assessment of sulphydryl blockage and oxidation, the determination of redox potentials, renin kinetics and the demonstration of reduced and oxidized forms of angiotensinogen, are given in Supplementary Methods.
Author Information Ethical approval was obtained for the use of all patient and control plasmas. Western blot SDS-PAGE of plasma exposed to N-ethylmaleimidepolyethylene-glycol adduct (mPEG). a, Plasma samples from adult controls show remarkably constant 40:60 proportions of the two forms, as do cord (venous umbilical) plasmas from healthy newborns-taken and stored with the maternal plasmas. R, reduced plasma treated with mPEG. b, Maternal plasma samples from pre-eclamptics and matched normotensive controls, as sequentially referred with blinded coding. The recognizably lower proportion of reduced angiotensinogen in pre-eclamptic plasmas was confirmed on breaking of the coding (normotensives black numerals, pre-eclamptics red, asterisked four samples self-evidently below the mean in c). c, Percentages of the reduced-form in pre-eclamptics (blue), mean 32 6 6%; and matched normotensive controls (black), mean 40 6 5% (means 6 s.d., n 5 12, P 5 0.004 by Student's t-test). See also Supplementary Fig. 6 .
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